Latvia IVD Market by Technology Molecular Diagnostics (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19), Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), Sequencing (Clinical, NIPT and Research Use Only) Geography (Latvia,), and forecast to 2029

Purchase Option

$ 3100
$ 4600
$ 6900

Latvia IVD market is valued at Euro 48.8 million in 2022 and is poised to grow at a significant CAGR of 3.2% over 2023–2029. The method of determining disease is by examining molecules in a tissue or fluid, such as proteins, DNA, and RNA referred to as the molecular diagnosis. There are various types of kits available for different diseases which are based application on molecular biology techniques. Various diseases which can be diagnosed by molecular diagnosis are Hepatitis B, Hepatitis C, HIV, CMV, EBV, STDs and respiratory infections etc. Hepatitis C is a liver infection caused by the hepatitis C virus and Hepatitis B virus (HBV) infection is a leading cause of liver disease-related morbidity and death. The two main types of tests available are assays for HCV antibodies and nucleic acid amplification testing to detect HCV RNA in blood. For HBV infection diagnosis, there are three primary blood tests available HBsAg (hepatitis B virus surface antigen), Anti-HBc (antibodies against the core antigen of the hepatitis B virus) and Anti-HBs (antibodies to HBsAg). Hospital acquired infection is any disease of bacterial, viral, parasitic, or fungal origin associated with a patient's hospitalization, exams, and treatment in a personal healthcare facility. Surgical site infections, catheter-associated urinary tract infections, ventilator-associated pneumonia and healthcare-associated pneumonia, infections linked with endoscopic treatments, and Clostridium difficile infections are the most common hospital-acquired infections in Latvia. According to the Latvian Center for Disease Prevention and Control, the frequency of hospital acquired infections is roughly 4% in the country, with over 8,000 people infected with at least one HAI. In 2020, 877.0 thousand COVID-19 PCR tests were conducted in Latvia, with the number of tests nearly doubling in 2020 to 4.6 million by the end of 2021. There are two types of tests available for the detection of current COVID-19 infection namely molecular and antigen. In 2021, a total of 4.6 Million COVID tests were conducted in Latvia.

Latvia IVD market Dynamics

In Latvia, high growth areas in infectious diseases are HPV, STDs, Respiratory Infections, Hospital Acquired Infection (HAIs), Oncology Markers. Human Papillomavirus (HPV) is most common cause of cervical cancer but most HPV-infected women do not develop cervical cancer. In 2021, Latvia HPV test value accounted for 21.8 thousand Euro and expected to reach 748.2 thousand Euro in 2029. Respiratory Infection is one of the most common infections among humans and is the main cause of mortality of children up to five years of age. Polymerase chain reaction (PCR), a molecular approach recently adopted in diagnostic laboratories, aids in the reasonably reliable diagnosis of M.pneumoniae and C.pneumoniae. Latvia has a high rate of hospitalizations for asthma, which is more than double the EU average (119 per 100 000 population versus 52 per 100 000 population). Death rates from respiratory diseases are on average 85% higher among men than among women in all EU countries. Human Bocavirus 1 (HBoV1) is one of the respiratory infections detected in Latvia and that the co-infection rate among HBoV1-positive cases is up to 90%. The most commonly detected co-infections with HBoV1 were HRV (37.50%), Adv. (35.42%), RSV A (29.17%), RSV B(20.83%), MPV (10.42%) and HEV (10.42%). In 2021, respiratory infections accounted for 308.8 thousand Euros and expected to reach 310.8 thousand Euros by 2029. Hospital-acquired infections (HAI) are gradually increasing in Latvia due to rise in a number of hospital admissions and grow in number of surgical procedures. Amongst the commonly isolated HAIs, gram-negative bacteria (GNBs) are of particular concern, especially given the significantly higher rate of associated complications. Among all the species, Escherichia spp., Klebsiella spp., and Acinetobacter spp. are most commonly observed infections in Latvia. E. coli contributed the around 35% of infections followed by Kebsiella spp. With 20% and Acinetobacter spp. With around 10%. Together, these three genera accounted for more than 60% of the total isolates. In 2021, Hospital acquired infection accounted for the market value of 923.7 thousand Euros and expected to reach 1.2 Mn Euros by 2029.

Latvia IVD Market Segmentation

By Technology
  • Molecular Diagnostics
    • Hepatitis C
    • Hepatitis B
    • Human Immunodeficiency Virus (HIV)
    • Cytomegalovirus (CMV)
    • Epstein–Barr virus (EBV)
    • Tuberculosis
    • Sexually Transmitted Diseases (STDs)
    • Hospital Acquired Infections
    • Respiratory Infections
    • Human Papillomavirus (HPV)
    • Covid- 19
By Technology
  • Tissue Diagnostics
    • H&E Stains
    • Special Stains
    • Advanced Stains
    • Digital Scanners
By Technology
  • Sequencing
    • Clinical
    • NIPT
    • Research Use Only

Frequently Asked Questions

The Latvia IVD market is valued at Euro 48.8 million in 2022 and is poised to grow at a significant CAGR of 3.2% over 2023–2029.

QIAGEN, Bio-Rad Laboratories, Roche Diagnostics, Thermofisher Scientific, Cepheid, Inc., Abbott, Inc., Seegene, Inc., Illumina, Inc., Zymo Research, MGI, Dako, Leica and abbott.

Covid-19 infection is accounted for the 4.6 Mn tests in 2021 and expected to reach 488.0 thousand tests by 2029.

Molecular diagnostics is expected to drive the market growth as it required for various diseases. Tissue Diagnostics is accounted for 356.7 thousand tests 2nd highest number of tests in 2021 and expected to reach 410.6 thousand tests by 2029.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • QIAGEN
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Thermofisher Scientific
  • Cepheid, Inc.
  • Abbott, Inc.
  • Seegene, Inc.
  • Illumina, Inc.
  • Zymo Research
  • MGI
  • Dako
  • Leica
  • Abbott

Adjacent Markets